COVID-19 Update #140 9/29/2022

In a 437 patient, Phase II/III trial (NCT04927065), Moderna’s bivalent COVID-19 vaccine, increased neutralizing antibodies against all Omicron subvariants, including BA.4 and BA.5 compared to the original Moderna vaccine in all participants regardless of prior infection.
 
A test-negative, case-control study by the CDC and academic partners, of 5,492 health care encounters for pregnant people, found the vaccine effectiveness (VE) for two doses to prevent COVID-19–associated emergency department and urgent care encounters during Omicron predominance was not significant, but VE for three doses was 79%. VE to prevent COVID-19 associated hospitalizations with was 86% for up to five months with two doses and up to four months with three doses.